Fast Five Quiz: Castration-Resistant Metastatic and Advanced Prostate Cancer Management

Evelyn S. Marienberg, MD


November 08, 2022

Patients with bone metastases should receive bone-targeting therapy. Either denosumab or zoledronic acid can be used in this setting, as Fizazi and colleagues demonstrated that denosumab was non-inferior to zoledronic acid for time to first skeletal-related event in men with CRPC and no previous exposure to intravenous bisphosphonate.

The TRAPEZE trial demonstrated that bone-directed therapies for bone metastatic CRPC had no effect on overall survival or progression-free survival in unadjusted analyses; however, analysis adjusted for all stratification variables did identify a benefit for strontium-89 on clinical progression-free survival and zoledronic acid for skeletal free interval.

ONJ is a rare toxicity of bone-targeting therapy; its incidence is 1%-2%, per the NCCN. Most of the patients who develop ONJ have preexisting dental problems. The NCCN recommends supplemental calcium and vitamin D for patients receiving bone-targeting therapy.

Learn more about bone-targeted therapy.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.